Wire · operational-macro
Safe to Try: The Simplest Way to Accelerate Cures and Bring Down Prescription Drug Prices
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 August 2026 · Fusion42 review
The article argues that the FDA should revert to focusing solely on drug safety for approval, not efficacy, to accelerate drug availability and reduce prescription costs. It claims the efficacy requirement has delayed drug approvals and increased costs without clear safety benefits.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
Changing FDA approval to focus only on safety opens a faster pathway to market for drug developers, cutting your time and cost to launch new therapies. This shift also highlights that proving efficacy might best happen through real-world use rather than lengthy trials.
◆ Coverage
1 source · 6 Aug 2026
◆ Related on Wire
◆ Topics